| 127.39 3.14 (2.53%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 153.19 | 1-year : | 178.93 |
| Resists | First : | 131.16 | Second : | 153.19 |
| Pivot price | 121.63 |
|||
| Supports | First : | 120.78 | Second : | 114.37 |
| MAs | MA(5) : | 120.26 |
MA(20) : | 123.1 |
| MA(100) : | 116.32 |
MA(250) : | 114.44 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 56.8 |
D(3) : | 36 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 159.88 | Low : | 55.25 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SRPT ] has closed below upper band by 17.3%. Bollinger Bands are 1.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 130.62 - 131.08 | 131.08 - 131.49 |
| Low: | 120.65 - 121.22 | 121.22 - 121.73 |
| Close: | 126.47 - 127.28 | 127.28 - 128.02 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
Semanteon Capital Management LP Purchases New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thu, 25 Apr 2024
Sarepta Therapeutics (SRPT) to Release Earnings on Wednesday - MarketBeat
Thu, 25 Apr 2024
Zacks Research Equities Analysts Decrease Earnings Estimates for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat
Thu, 25 Apr 2024
Bullish Sarepta Therapeutics Insiders Loaded Up On US$13.3m Of Stock - Yahoo Canada Finance
Wed, 24 Apr 2024
This Is What Whales Are Betting On Sarepta Therapeutics - Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
Wed, 24 Apr 2024
Sarepta Therapeutics to Announce First Quarter 2024 Financial Results - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 90 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 87.7 (%) |
| Shares Short | 4,600 (K) |
| Shares Short P.Month | 4,780 (K) |
| EPS | -5.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.17 |
| Profit Margin | -43.2 % |
| Operating Margin | 6.2 % |
| Return on Assets (ttm) | -5.3 % |
| Return on Equity (ttm) | -86.2 % |
| Qtrly Rev. Growth | 53.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 13.21 |
| EBITDA (p.s.) | -2.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -501 (M) |
| Levered Free Cash Flow | -348 (M) |
| PE Ratio | -21.97 |
| PEG Ratio | 0.5 |
| Price to Book value | 13.89 |
| Price to Sales | 9.64 |
| Price to Cash Flow | -23.87 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|